Researchers at the Medical University of Wrocław have identified fatigue as the leading factor behind poor adherence to treatment among patients with relapsing-remitting multiple sclerosis (MS).
The study found that while modern therapies, including high-efficacy disease-modifying treatments, are increasingly available in Poland, their effectiveness is often limited by patients not following prescribed regimens. Using the Adherence in Chronic Diseases Scale (ACDS), researchers recorded moderate adherence levels, with chronic fatigue emerging as the most significant barrier.
“Fatigue in MS is not something patients can simply ‘sleep off’,” explained Dr. Justyna Chojdak-Łukasiewicz from the Department of Neurology. “It’s a profound physical and mental exhaustion that directly reduces patients’ ability to maintain consistent treatment.”
The study also revealed that depression, while common in MS, was less predictive of adherence than disease acceptance, which strongly correlated with better compliance.
Despite robust national treatment programmes and reimbursement for MS therapies, researchers emphasised the need for a comprehensive approach combining patient education, fatigue management strategies, rehabilitation, psychological support, and digital tools such as medication reminder apps.
“Even small interventions – asking ‘Have you taken your medication today?’ or adjusting daily routines – can help improve long-term outcomes,” added Dr. Chojdak-Łukasiewicz, stressing that MS treatment is “a marathon, not a sprint.”
The findings also highlight the role of family support, encouraging loved ones to help organise daily tasks, monitor medication schedules, and create a supportive environment.
Source: Medical University of Wrocław
About the Author
